XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.3
Business and Geographical Reporting Segments
 9 Months Ended
Sep. 30, 2025
Business and Geographical Reporting Segments [Abstract]  
Business and Geographical Reporting Segments
Note 13
Business and Geographical Reporting Segments:

The Company has organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC and TheraClear procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses, as well as settlement gains. Interest and other financing income (expense) is also not allocated to the operating segments.
The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

   
Three Months Ended September 30, 2025
    
Nine Months Ended September 30, 2025
  
   
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
    
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
  
                                     
Revenues, net
  
$
5,546
    
$
1,383
    
$
6,929
    
$
15,392
    
$
6,012
    
$
21,404
  
Cost of revenues
    
2,130
       615      
2,745
      
6,003
      
3,134
      
9,137
  
Gross profit
    
3,416
      
768
      
4,184
      
9,389
      
2,878
      
12,267
  
Gross profit %
    
61.6
%
    
55.5
%
    
60.4
%
    
61.0
%
    
47.9
%
    
57.3
%
                                                 
Allocated expenses:
                                                
Engineering and product development
    
138
      
34
      
172
      
261
      
93
      
354
  
Selling and marketing
    
2,562
      
639
      
3,201
      
7,087
      
2,770
      
9,857
  
Unallocated expenses:
                                                
General and administrative
    
—
      
—
      
2,668
      
—
      
—
      
7,928
  
Settlement gains
    
—
      
—
      
(684
)
    
—
      
—
      
(684
)
Total allocated and unallocated expenses
    
2,700
      
673
      
5,357
      
7,348
      
2,863
      
17,455
  
Income (loss) from operations
    
716
       95      
(1,173
)
    
2,041
       15      
(5,188
)
Interest expense
    
—
      
—
      
(498
)
    
—
      
—
      
(1,475
)
Interest income
    
—
      
—
      
49
      
—
      
—
      
344
  
Net income (loss)
  
$
716
    
$
 95    
$
(1,622
)
  
$
2,041
    
$
 15    
$
(6,319
)

   
Three Months Ended September 30, 2024
    
Nine Months Ended September 30, 2024
  
   
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
    
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
  
                                     
Revenues, net
  
$
5,381
    
$
3,416
    
$
8,797
    
$
15,416
    
$
8,570
    
$
23,986
  
Cost of revenues
    
1,861
      
1,650
      
3,511
      
5,806
      
4,721
      
10,527
  
Gross profit
    
3,520
      
1,766
      
5,286
      
9,610
      
3,849
      
13,459
  
Gross profit %
    
65.4
%
    
51.7
%
    
60.1
%
    
62.3
%
    
44.9
%
    
56.1
%
                                                 
Allocated expenses:
                                                
Engineering and product development
    
180
      
63
      
243
      
521
      
162
      
683
  
Selling and marketing
    
2,542
      
485
      
3,027
      
7,974
      
1,241
      
9,215
  
Unallocated expenses:
                                                
General and administrative
    
—
      
—
      
3,621
      
—
      
—
      
8,531
  
Total allocated and unallocated expenses
    
2,722
      
548
      
6,891
      
8,495
      
1,403
      
18,429
  
Income (loss) from operations
    
798
      
1,218
      
(1,605
)
    
1,115
      
2,446
      
(4,970
)
Interest expense
    
—
      
—
      
(537
)
    
—
      
—
      
(1,592
)
Interest income
    
—
      
—
      
68
      
—
      
—
      
167
  
Other income
    
—
      
—
      
—
      
—
      
—
      
864
  
Net income (loss)
  
$
798
    
$
1,218
    
$
(2,074
)
  
$
1,115
    
$
2,446
    
$
(5,531
)
The following table presents depreciation and amortization by reportable segment for the periods indicated below (in thousands):

   
Three Months Ended
September 30,
    
Nine Months Ended
September 30,
  
   
2025
    
2024
    
2025
    
2024
  
                         
Dermatology recurring procedures
  
$
841
    
$
1,065
    
$
3,070
    
$
3,259
  
Dermatology procedures equipment
    
23
      
171
      
231
      
469
  
Unallocated expenses
    
—
      
3
      
1
      
10
  
Total
  
$
864
    
$
1,239
    
$
3,302
    
$
3,738
  

The following tables present the Company’s revenue disaggregated by geographical region for the periods indicated below (in thousands). Domestic refers to revenue from customers based in the United States, and foreign revenue is derived from the Company’s distributors primarily in Asia.

   
Three Months Ended September 30, 2025
    
Nine Months Ended September 30, 2025
  
   
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
    
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
  
                                     
Domestic
  
$
5,076
    
$
142
    
$
5,218
    
$
13,987
    
$
688
    
$
14,675
  
China
    
—
      
130
      
130
      
—
      
2,623
      
2,623
  
Middle East
    
—
      
172
      
172
      
—
      
1,190
      
1,190
  
Other foreign
    
470
      
939
      
1,409
      
1,405
      
1,511
      
2,916
  
Total
  
$
5,546
    
$
1,383
    
$
6,929
    
$
15,392
    
$
6,012
    
$
21,404
  

   
Three Months Ended September 30, 2024
    
Nine Months Ended September 30, 2024
  
   
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
    
Dermatology Recurring Procedures
    
Dermatology Procedures Equipment
    
Total
  
                                     
Domestic
  
$
4,893
    
$
677
    
$
5,570
    
$
14,136
    
$
1,275
    
$
15,411
  
China
    
—
      
1,045
      
1,045
      
—
      
3,165
      
3,165
  
Middle East
    
—
      
724
      
724
      
—
      
1,438
      
1,438
  
Other foreign
    
488
      
970
      
1,458
      
1,280
      
2,692
      
3,972
  
Total
  
$
5,381
    
$
3,416
    
$
8,797
    
$
15,416
    
$
8,570
    
$
23,986
  

The following table presents total assets by reportable segment (in thousands):

   
September 30, 2025
    
December 31, 2024
  
             
Dermatology recurring procedures
  
$
17,455
    
$
20,521
  
Dermatology procedures equipment
    
5,495
      
5,081
  
Other unallocated assets
    
7,767
      
9,326
  
Total
  
$
30,717
    
$
34,928
  

Long-lived assets of $1.2 million and $1.3 million were located in international markets, primarily Korea and Japan, as of September 30, 2025 and December 31, 2024, respectively, with the remainder located in domestic markets.